Cooler weather doesn't mean these stocks won't heat up this month.
News & Analysis: Novavax
Novavax's RSV vaccine may not be dead after all.
NVAX earnings call for the period ending June 30, 2019.
Catalyst Pharmaceuticals and Novavax have had tough go of it in May. Could better days be close at hand?
Novavax's proposed reverse split has investors on edge.
Novavax's first-quarter earnings report didn't provide the answers investors were looking for.
NVAX earnings call for the period ending March 31, 2019.
Investors' optimism about the prospects for the biotech's experimental vaccines appears to be increasing.
Novavax needs a deep-pocketed partner soon.
The beleaguered biotech is down but not out.